Patrys

About

Company History

Patrys listed on the Australian Stock Exchange (ASX) in 2007 to develop new therapies for the treatment of cancer. It continues to leverage its expertise in antibody development through more recent work developing a novel, versatile antibody platform called deoxymabs as human therapeutic agents for treatment and management of cancer. In 2016, Patrys secured an exclusive, worldwide license from Yale University for the use of deoxymab antibodies. A collaboration with Monash University is continuing to assess the impact of the deoxymabs PAT-DX1 and PAT-DX3 on vasculitis.

In 2026, Patrys completed the acquisition of Australian drug reformulation company Reliis, marking an important milestone in its strategy to broaden its clinical-stage therapeutic pipeline with a differentiated, lower-risk asset with a clear path to market. The acquisition included a program to develop an intravenous formulation of quetiapine, — a drug with existing safety and efficacy data — targeting the significant unmet market of acute delirium.

By building on established quetiapine data, population pharmacokinetic modelling, and hybrid regulatory pathways, the company expects a shorter, more predictable development timeline with clear regulatory precedent — backed by strong clinician demand — enabling faster market entry and adoption. The acquisition is designed to bridge timeline gaps and reduce development risk, generating nearer-term value for Patrys.

Board of Directors

Our Board is comprised of respected global leaders in drug development, clinical research and commercialisation.

Peter Christie

Non-Executive Chairman

Peter Christie is a qualified accountant and tax agent with over 25 years of experience in public accounting. He has served on the boards of several public companies in the resource sector since 2006 and has developed extensive interests in hospitality and property development.

Mr. Christie is the Director of Hawkins Christie Management Services, a firm based in Nedlands, Western Australia, providing accounting and management services. He is also the current President of the South Fremantle Football Club, a role he has held since 2018, following over a decade of service on the club’s board. His leadership has been instrumental in the club’s strategic growth and community engagement initiatives.

In addition to his roles in the resource sector and community sports, Mr. Christie has experience in the medical industry, having previously served as Chairman of Safety Medical Products Limited. His diverse background in finance, corporate governance, and community leadership positions him as a valuable asset to the board.

Brian Leedman

Non-Executive Director

Mr Leedman is a biotech entrepreneur with a strong ASX track record, having co-founded several healthcare companies, including ResApp Health, acquired by Pfizer in 2022 and Imugene Limited.

He has extensive board and leadership experience, serving as Chairman or Director of multiple ASX-listed companies including Alcidion, Oncosil NeuroScientific Biopharmaceuticals and Blinklab.

With a background in investor relations and corporate strategy, Mr Leedman has spent a decade as VP of Investor Relations at pSivida (now EyePoint Therapeutics), plus senior roles at Westpac and Ernst & Young.

Dr Anton Uvarov

Non-Executive Director

Dr Uvarov has significant experience in the healthcare industry with a particular focus on neuroscience. Dr Uvarov has started his career in biotechnology investments as equities analyst with Citigroup. He is aco-founding director of several publicly listed companies in Australia including clinical stage companies such as BlinkLab (ASX:BB1), Dimerix (ASX:DXB), Actinogen Medical (ASX:ACW) and Neuroscientific Biopharmaceuticals (ASX:NSB). He was previously on the board of late-stage clinical oncology company Imugene (ASX:IMU).

Ms Leanne Kite

Non-Executive Director

Ms Kite has extensive experience in finance, governance and investor relations with 20+ years across biotech, resources and energy, and was the co-founder of Reliis where she led strategy, capital formation and governance.

Previously Ms Kite leveraged her strong capital markets and institutional engagement background while leading Investor Relations for Liontown Resources, an ASX 200 company. She also held prior senior finance and strategy roles at Woodside Energy.

Ms Kite is a Chartered Accountant and AICD Graduate, bringing large-cap governance capability and early-stage biotech leadership to the Board.

Mr Dino Cercarelli

Non-Executive Director

Dino Cercarelli is a healthcare and clinical research executive with over 20 years’ experience leading clinical trial operations, governance frameworks and multidisciplinary teams across major Australian health organisations. He is currently Chief Operating Officer of the Australian Clinical Trials Alliance (ACTA), where he oversees national operations, governance, financial management, risk and workforce development, and has strengthened organisational systems and delivery of major national initiatives.

Previously, he spent eight years at St John of God Health Care leading research and clinical trial operations, implementing governance frameworks and supporting a large portfolio of trials, including establishing a First-in-Human Phase I oncology study. He is also co-founder and former Managing Director of Reliis, contributing to its recognition as WA Innovator of the Year.

Mr Cercarelli holds an MBA and postgraduate qualifications in business and health services management and contributes to several national clinical research committees.

Management

Our Management Team are long-standing employees and highly capable professionals, with a cross-section of skills and experience targeted to our needs.

Dr Samantha South BSc (Hons), PhD, MBA GAICD

Chief Executive Officer

Dr Samantha South is an experienced biotech executive with deep expertise in CNS drug development, having guided multiple preclinical assets to clinical readiness across listed and unlisted environments.

She has spent her career cultivating expertise in drug development, management of non-clinical studies, project management, contracts and intellectual property, manufacturing, regulatory and clinical operations.

As a founding Executive Director of ASX-listed Argenica Therapeutics (AGN), she served as COO and VP of Nonclinical Development, and has held Director roles across multiple UWA spin-outs including MiReven, Eridan Technologies, OncoRes Medical, OxiDx, and Rage Biotech.

Her scientific foundation spans CNS research at Weill Cornell, UQ, and the Garvan Institute, co-authoring many publications and successful grants. As Preclinical Manager at TetraQ, she specialised in CNS animal models and IND-enabling non-clinical studies.

Valentina Dubljevic

Vice President, Research and Development, MBB, BSc, GAICD

Ms. Dubljevic joined Patrys in June 2012 and is responsible for the pre-clinical and clinical development of Patrys’ products. Ms. Dubljevic brings more than 20 years of scientific and commercial experience in the areas of anti- cancer therapies, vaccine development, and diagnostics.

Prior to joining Patrys, she worked at Monash University conducting research on malaria vaccine development; at Cytopia Limited developing small molecule anti-cancer drugs and at Monash Institute of Medical Research (MIMR) developing antibody therapies for cancer. She has extensive experience related to the drug development, management of pre-clinical studies, manufacturing, regulatory and clinical operations, contracts and project management and has co-authored multiple scientific papers and grants.

Ms. Dubljevic holds a Bachelor of Biomedical Science degree from Griffith University, Brisbane, a Masters in Biotechnology and Business degree from RMIT and is a graduate of the Australian Institute of Company Directors (GAICD).

Menu